Recent research from Stanford Medicine has identified a naturally occurring molecule called BRP that may influence appetite suppression and body weight regulation. This peptide appears to act on a specific brain region, the hypothalamus, which is central to controlling hunger and metabolism. The findings, published in Nature, suggest a potentially more targeted approach compared to current drugs such as semaglutide, the active ingredient in Ozempic.
Distinct Mechanism Compared to Semaglutide
Semaglutide targets receptors found in multiple tissues including the brain, gut, and pancreas, which contributes to its broad effects such as slowed digestion and lowered blood sugar. In contrast, BRP seems to act primarily within the hypothalamus, potentially reducing appetite without some of the common side effects seen with semaglutide like nausea, constipation, or muscle loss.
Discovery Enabled by Artificial Intelligence
The identification of BRP was facilitated by an AI-based algorithm named Peptide Predictor. This tool scanned human protein-coding genes to predict peptides generated by the enzyme prohormone convertase 1/3, which is involved in processing prohormones into active peptides. From thousands of candidates, researchers focused on peptides likely to affect neuronal activity and energy balance.
BRP, a small 12-amino-acid peptide derived from the prohormone BRINP2, produced a notably strong activation of neuron-like cells in laboratory tests, surpassing that of GLP-1, a well-known peptide involved in appetite regulation.
Animal Studies Show Promising Results
In experimental studies, BRP injections before feeding reduced food intake by up to 50% in lean mice and minipigs, the latter being a model closer to human metabolism. Obese mice treated daily with BRP for two weeks lost body fat and showed improved glucose and insulin tolerance, indicators of metabolic health.
Importantly, behavioural assessments found no significant changes in activity, anxiety-like behaviour, or digestion, suggesting a favourable side effect profile compared to existing treatments.
Next Steps and Considerations
Current evidence remains limited to animal models. Researchers are working to identify the specific receptors BRP binds to and to understand the downstream biological pathways involved. A challenge is the peptide’s rapid breakdown in the body, and efforts are underway to enhance its stability for potential future use.
These findings contribute to evolving weight science by highlighting peptides as precise modulators of appetite and metabolism. Such research informs the development of novel interventions but requires further clinical validation.
For those interested in peptide research and product literacy, Svelta Labs offers detailed resources and products designed to support understanding of peptide science in wellbeing contexts. Visit https://sveltalabs.com for more information.
Research Use Disclaimer: This article summarises early-stage scientific findings and does not constitute medical advice or endorsement of any specific treatment. The safety and efficacy of BRP in humans have not been established.